AstraZeneca’s patent on asthma drug invalidated by U.S. court – Business Insider

AstraZeneca's patent on asthma drug invalidated by U.S. court
Business Insider
NEW YORK (Reuters) – A U.S. federal judge ruled late on Friday that AstraZeneca PLC's patent on its Pulmicort Repsules treatment for asthma was invalid, opening up the market to a second, cheaper generic version. Actavis Plc said that the U.S. District …
AstraZeneca plc (ADR) Patent On Asthma Drug Declared Invalid By US CourtBidness ETC
AstraZeneca loses its US patent rights for asthma drug Pulmicort RespulesCITY A.M.

all 37 news articles »